UnitedHealth Group Inc

UNH remains in a Stage 2 advancing phase with Parabola-driven acceleration, yet the recent pullback into the rising 9 and 20 EMAs presents a tactical buy-the-dip opportunity aligning with the bullish medium- and long-term trend.

• ↑Q2 2026 EPS $4.85 (+18.9% YoY) reflects strong earnings growth.
• ↑Optum segment boosts margins via disciplined pricing and service mix.
• ↓Projected Q2 revenue down 0.7% to $110.8B hints at growth stall.